It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
- Meiji Gets Thailand/Indonesia Rights to Toray’s Remitch
January 21, 2019
- Opdivo Wins Label Expansion for NSCLC in Taiwan: Ono
January 21, 2019
- Eisai’s Voluntary Redundancy Program Draws 300 Applicants in 1st Round, 3 Times More than Planned
January 21, 2019
- Chugai Files Gene Panel Test for Use as Companion Diagnostic to Entrectinib
January 21, 2019
- Novo to Cease Dealings with 6 Wholesalers from April to Cut Distribution Costs
January 21, 2019
- Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
- Ethical Drug Sales Slip 0.2% in November: Crecon
January 18, 2019
- Astellas, AstraZeneca Wind Up Symbicort Collaboration
January 18, 2019
- Takeda Becomes 1st Japan Drug Maker to Ring Opening Bell at NYSE
January 16, 2019
- Daiichi Sankyo Launches PIII DS-8201 Study in HER2-Low Breast Cancer
January 16, 2019
- Beverage Maker DyDo to Enter Orphan Drug Field Aiming at “Second Pillar of Business”
January 16, 2019
- Insomnia Treatment Lemborexant Filed for US Approval: Eisai, Purdue Pharma
January 16, 2019
- Fujifilm to Introduce Automatic Aseptic Filling System in US Bio CDMO Hub
January 16, 2019
- Mitsubishi Tanabe Stepping Up Rupafin Promotion in November: Anterio
January 15, 2019
- Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
- Avastin Top-Seller Medicine in Japan in December: Encise Snapshot
January 11, 2019
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Wakamoto Kicks Off Japan PIII for Glaucoma Drug
January 11, 2019
- Fujifilm’s Next-Generation Technology Doubles Antibody Productivity, Reduces Production Time by 30%
January 11, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…